Ken Griffin Avidity Biosciences, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$37.21 - $48.14 $1.07 Million - $1.39 Million	28,800 Added 228.57%	41,400 $1.9 Million
Q2 2024 Aug 14, 2024	SELL	$22.73 - $40.85 $325,039 - $584,155	-14,300 Reduced 53.16%	12,600 $514,000
Q1 2024 May 15, 2024	BUY	$9.16 - $25.52 $170,376 - $474,672	18,600 Added 224.1%	26,900 $686,000
Q4 2023 Feb 14, 2024	SELL	$4.87 - $9.37 $49,674 - $95,573	-10,200 Reduced 55.14%	8,300 $75,000
Q3 2023 Nov 14, 2023	BUY	$6.3 - $11.35 $80,010 - $144,145	12,700 Added 218.97%	18,500 $118,000
Q2 2023 Aug 14, 2023	SELL	$10.62 - $17.34 $53,099 - $86,700	-5,000 Reduced 46.3%	5,800 $64,000
Q1 2023 May 15, 2023	SELL	$15.35 - $25.65 $130,475 - $218,025	-8,500 Reduced 44.04%	10,800 $165,000
Q4 2022 Feb 14, 2023	SELL	$10.06 - $22.66 $374,232 - $842,952	-37,200 Reduced 65.84%	19,300 $428,000
Q3 2022 Nov 14, 2022	SELL	$15.46 - $23.43 $1.88 Million - $2.85 Million	-121,700 Reduced 68.29%	56,500 $923,000

256

107M

224K

161K

Ticker RNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,127,000
Market Cap $2.28B
Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.